Assessing cost-effectiveness of drug interventions for schizophrenia

Australian and New Zealand Journal of Psychiatry

Volumn 39, Issue 1-2, 2005, Pages 44-54

  Magnus, Anne ^a   Carr, Vaughan ^b   Mihalopoulos, Cathrine ^c   Carter, Rob ^c   Vos, Theo ^a  

^a Public Health   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Clozapine; DALY; Olanzapine; Outcomes; Risperidone; Side effects

Indexed keywords

BENZATROPINE MESILATE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; AUSTRALIA; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; HEALTH CARE COST; HEMATOLOGIC DISEASE; HUMAN; LOW DRUG DOSE; MALE; MEDICAL ASSESSMENT; METHODOLOGY; PATIENT SATISFACTION; PHYSICAL DISABILITY; PHYSICIAN; PRESCRIPTION; PREVALENCE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; STANDARDIZATION; SUICIDE; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; AUSTRALIA; BENZODIAZEPINES; CLOZAPINE; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; HUMANS; NATIONAL HEALTH PROGRAMS; QUALITY-ADJUSTED LIFE YEARS; RISPERIDONE; SCHIZOPHRENIA;

EID: 9644299062     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2005.01509.x     Document Type: Article

References (62)

1. American Psychiatric Association. Practice Guidelines for the Treatment of Schizophrenia. Washington DC: American Psychiatric Press, 1996.
2. Access Economics. Schizophrenia: costs an analysis of the burden of schizophrenia and related suicide in Australia. Melbourne: SANE Australia, 2002.
3. Awad AG, Voruganti LNP. Quality of life and new antipsychotics in schizophrenia. Are patients better off? International Journal of Social Psychiatry 1999; 45:268-275.
4. McGorry P, Killackey E, Lambert M, Lambert T. Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia (2003). Australasian Psychiatry 2003; 11:136-147.
5. National Institute for Clinical Excellence. Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. London: National Collaborating Centre for Mental Health, 2002
6. Haby M, Carter R, Mihalopoulos C et al. Assessing cost-effectiveness - Mental health. Introduction to the study and methods. Australian and New Zealand Journal of Psychiatry 2004; 38: 569-578.
7. Jablensky A, McGrath J, Herrman H et al. People living with psychotic illness: an Australian study 1997-98. Canberra: Department of Health and Aged Care, 1999.
8. Lewin TJ, Carr VJ. Rates of treatment of schizophrenia by general practitioners. A pilot study. Medical Journal of Australia 1998; 168:166-169.
9. Harding CM, Brooks GW, Ashigawa T, Strauss JS, Breier A. The Vermont Longitudinal Sudy of persons with severe mental illness, 1: Methodology, study sample, and overall status 32 years later. American Journal of Psychiatry 1987; 144:718-726.
10. Ciompi L. Three lectures in schizophrenia. The natural history of schizophrenia in the long term. British Journal of Psychiatry 1980; 136: 413-420.
11. Helgason L. Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatrica Scandinavica 1990; 81:231-235.
12. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J. Recovery from psychotic illness: a 15- and 25-year international follow-up study. British Journal of Psychiatry 2001; 178:506-517.
13. Huber G, Gross G, Schuttler R, Linz M. Longitudinal studies of schizophrenic patients. Schizophrenia Bulletin 1980; 6:592-605.
14. Gaebel W. Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. International Clinical Psychopharmacology 1997; 12:S37-S42.
15. Marder SR. Facilitating compliance with antipsychotic medication. Journal of Clinical Pharmacology 1998; 58:21-25.
16. Harris E, Barraclough B. Excess mortality of mental disorder. British Journal of Psychiatry 1998; 173:11-53.
17. Gureje O, Herrman H, Harvey C, Morgan V, Jablensky A. The Australian national survey of psychotic disorders: profile of psychosocial disability and its risk factors. Psychological Medicine 2002; 32:639-647.
18. Stouthard M, Essink-Bot M, Bonsel G et al. Disability Weights for Diseases in the Netherlands. Rotterdam: Department of Public Health Erasmus University, 1997.
19. Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software, 2003.
20. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software, 2003.
21. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software, 2003.
22. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication versus clozapine for schizophrenia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software, 2003.
23. Wahlbeck K, Cheine M, Essali M. Clozapine versus typical neuroleptic medication for schizophrenia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software, 2003.
24. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal of 2000; 321:1371-1376.
25. Waraich P, Adams CE, Roque M, Hamill K, Marti J. Haloperidol dose for the acute phase of schizophrenia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software, 2003.
26. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. The New England Journal of Medicine 2002; 346:16-22.
27. Egger M, Smith G, Altman D. Systematic reviews in health care: meta-analysis in context, 2nd edn. London: BMJ, 2001.
28. Willett W, Manson J, Stampfer M et al. Weight, weight change and coronary heart disease in women: risk within the 'normal' weight range. Journal of the American Medical Society 1995; 273:461-465.
29. Rexrode K, Hennekens C, Willett W et al. A prospective study of body mass index, weight change and risk of stroke in women. Journal of American Medical Association 1997; 275:447-451.
30. Lee I, Paffenbarger RJ. Quetelet's index and risk of colon cancer in college alumni. Journal of the National Cancer Institute 1992; 84:1326-1331.
31. Colditz G, Willett W, Rotnitsky A, Manson J. Weight gain as a risk factor for clinical diabetes mellitus in women. Annals of Internal Medicine 1995; 122:481-486.
32. Department of Human Services. Victorian Burden of Disease Study: morbidity. Melbourne: Department of Human Services, 1999.
33. Duggan A, Warner J, Knapp M, Kerwin R. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. British Journal of Psychiatry 2003; 182:505-508.
34. Hamilton SH, Edgell ET, Revicki DA, Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European subsample. International Clinical Psychopharmacology 2000; 15:245-255.
35. Tran PV, Hamilton SH, Kuntz AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 1997; 17:407-418.
36. Rosenheck R, Cramer J, Xu W et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 1997; 337:809-815.
37. Voruganti L, Cortese L, Oyewumi L, Cemovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 2000; 43:135-145.
38. Hellewell J. Patients' subjective experiences of antipsychotics. Clinical relevance. CNS Drugs 2002; 16:457-471.
39. Emsley RA, Risperidone Working Group. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophrenia Bulletin 1999; 25:721-729.
40. Coulter DM, Bare A, Meyboom RHB, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. British Medical Journal 2001; 322:1207-1209.
41. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354:1841-1845.
42. Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatric Services 1996; 47:853-858.
43. Gureje O, Herrman H, Harvey C, Trauer T, Jablensky A. Defining disability in psychosis: Performance of the diagnostic interview for psychosis-disability module (DIP-DIS) in the Australian national survey of psychotic disorders. Australian and New Zealand Journal of Psychiatry 2001; 35:846-851.
44. Davis J, Chen N, Glick I. A Meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003; 60:553-564.
45. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000; 17:383-389.
46. Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost-effectiveness clinical decision analysis model for schizophrenia. American Journal of Managed Care 1998; 4:345-355.
47. Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. Journal of Clinical Psychiatry 1997; 58:50-54.
48. Albright P, Livingstone S, Keegan DL, Ingham M, Shrikhande S, Le Lorier J. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy. Clinical Pharmacoeconomics 1996; 11:289-299.
49. Geddes J. Generating evidence to inform policy and practice: The example of the second generation 'atypical' antipsychotics. Schizophrenia Bulletine 2003; 29:105-114.
50. Carr VJ, Neil AL, Halpin SA, Holmes S, Lewin TJ. Costs of schizophrenia and other psychoses in urban Australia: findings from the low prevalence (psychotic) disorders study. Australian and New Zealand Journal of Psychiatry 2003; 37:31-40.
51. Davies A, Adena MA, Keks NA, Catts SV, Lambert T, Schweitzer I. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clinical Therapeutics 1998; 20:58-71.
52. Jablensky A. Epidemiology of schizophrenia. Australasian Epidemiologist 2002; 9:2-8.
53. Sanderson K, Andrews G, Corry J, Lapsley H. Using the effect size to model change in preference values from descriptive health stares. Quality of Life Research 2004; 13:1255-1264.
54. Carr VJ, Neil AL, Halpin SA, Holmes S. Costs of psychosis in urban Australia. A bulletin of the low prevalence disorders study. Newcastle: Centre for Mental Health Studies and the University of Newcastle. 2000.
55. Britt H, Miller G, Knox C et al. General practice activity in Australia 2000-01. AIHW Cat. No. GEP8. Canberra: Australian Institute of Health and Welfare, 2001. (General Practice Series no. 8.)
56. Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I. Risperidone versus haloperidol: II. Cost-effectiveness. Clinical Therapeutics 1998; 20:196-212.
57. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised control trials. Schizophrenia Research 1999; 35:51-68.
58. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999; 156:1686-1696.
59. Beasley CM, Tollefson GD, Tran PV, Satterlee W, Sanger T, Hamilton SH. Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111-123.
60. Mauskopf JA, Muroff M, Gibson PJ, Grainger DL. Estimating the costs and benefits of new ding therapies: atypical antipsychotic drugs for schizophrenia. Schizophrenia Bulletin of the 2002; 28:619-635.
61. Rosenheck R, Cramer J, Xu W et al. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatmnent of refractory schizophrenia. Health Services Research 1998; 33:1237-1267.
62. Zhao Z. A retrospective evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Managed Care Interface 2002; 15:75-81.